Latest Insider Transactions at Eli Lilly & CO (LLY)
This section provides a real-time view of insider transactions for Eli Lilly & CO (LLY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ELI LILLY & Co to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ELI LILLY & Co's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 04
2017
|
Susan Mahony SVP & Pres., Lilly Oncology |
SELL
Open market or private sale
|
Direct |
36,585
-40.0%
|
$3,146,310
$86.18 P/Share
|
|
Dec 04
2017
|
Alfonso G Zulueta SVP & President, Lilly Int'l |
SELL
Open market or private sale
|
Direct |
3,532
-8.1%
|
$303,752
$86.0 P/Share
|
|
Dec 03
2017
|
David A Ricks President, Chair, and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,601
-2.36%
|
$221,085
$85.32 P/Share
|
|
Dec 03
2017
|
David A Ricks President, Chair, and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,496
+4.76%
|
-
|
|
Dec 03
2017
|
Stephen F Fry SVP, HR & Diversity |
SELL
Payment of exercise price or tax liability
|
Direct |
3,567
-4.12%
|
$303,195
$85.32 P/Share
|
|
Dec 03
2017
|
Stephen F Fry SVP, HR & Diversity |
BUY
Exercise of conversion of derivative security
|
Direct |
7,557
+8.03%
|
-
|
|
Dec 03
2017
|
Donald A Zakrowski SVP, Finance, & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,070
-25.68%
|
$90,950
$85.32 P/Share
|
|
Dec 03
2017
|
Donald A Zakrowski SVP, Finance, & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,281
+44.05%
|
-
|
|
Nov 20
2017
|
Ellen R Marram Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,924
+3.5%
|
$159,692
$83.18 P/Share
|
|
Nov 20
2017
|
Carolyn R Bertozzi Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,763
+50.0%
|
$146,329
$83.18 P/Share
|
|
Nov 20
2017
|
Michael L Eskew Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,924
+4.97%
|
$159,692
$83.18 P/Share
|
|
Nov 20
2017
|
Jackson P Tai Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,924
+3.64%
|
$159,692
$83.18 P/Share
|
|
Nov 20
2017
|
Franklyn G Prendergast Director |
BUY
Grant, award, or other acquisition
|
Direct |
802
+1.16%
|
$66,566
$83.18 P/Share
|
|
Nov 20
2017
|
Kathi P Seifert Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,924
+2.74%
|
$159,692
$83.18 P/Share
|
|
Nov 20
2017
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,055
+4.99%
|
$170,565
$83.18 P/Share
|
|
Nov 20
2017
|
Katherine Baicker Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,924
+11.42%
|
$159,692
$83.18 P/Share
|
|
Nov 20
2017
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,040
+28.24%
|
$169,320
$83.18 P/Share
|
|
Nov 20
2017
|
William G Kaelin Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,924
+12.52%
|
$159,692
$83.18 P/Share
|
|
Nov 20
2017
|
Jamere Jackson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,924
+43.94%
|
$159,692
$83.18 P/Share
|
|
Nov 20
2017
|
Marschall S Runge Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,924
+17.17%
|
$159,692
$83.18 P/Share
|
|
Nov 20
2017
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,924
+3.22%
|
$159,692
$83.18 P/Share
|
|
Nov 20
2017
|
R David Hoover Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,924
+5.04%
|
$159,692
$83.18 P/Share
|
|
Nov 10
2017
|
Alfonso G Zulueta SVP & President, Lilly Int'l |
SELL
Open market or private sale
|
Direct |
2,003
-4.39%
|
$166,249
$83.67 P/Share
|
|
Nov 03
2017
|
Susan Mahony SVP & Pres., Lilly Oncology |
SELL
Bona fide gift
|
Direct |
15,861
-28.9%
|
-
|
|
Oct 16
2017
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
127
+0.34%
|
$10,795
$85.95 P/Share
|
|
Oct 16
2017
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
112
+3.44%
|
$9,520
$85.95 P/Share
|
|
Oct 04
2017
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
205,000
-0.17%
|
$17,630,000
$86.81 P/Share
|
|
Sep 29
2017
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
195,000
-0.08%
|
$16,575,000
$85.29 P/Share
|
|
Sep 18
2017
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
132
+0.36%
|
$10,824
$82.52 P/Share
|
|
Sep 18
2017
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
117
+3.72%
|
$9,594
$82.52 P/Share
|
|
Sep 15
2017
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
190,000
-0.08%
|
$15,580,000
$82.91 P/Share
|
|
Aug 31
2017
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
180,000
-0.15%
|
$14,580,000
$81.06 P/Share
|
|
Aug 21
2017
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
141
+0.38%
|
$10,857
$77.38 P/Share
|
|
Aug 21
2017
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
125
+4.14%
|
$9,625
$77.38 P/Share
|
|
Jul 31
2017
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
220,000
-0.09%
|
$18,260,000
$83.38 P/Share
|
|
Jul 17
2017
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
131
+0.36%
|
$10,873
$83.64 P/Share
|
|
Jul 17
2017
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
116
+4.02%
|
$9,628
$83.64 P/Share
|
|
Jun 22
2017
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
210,000
-0.17%
|
$17,640,000
$84.43 P/Share
|
|
Jun 20
2017
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
215,000
-0.17%
|
$17,845,000
$83.05 P/Share
|
|
Jun 19
2017
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
133
+0.36%
|
$10,906
$82.34 P/Share
|
|
Jun 19
2017
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
117
+4.22%
|
$9,594
$82.34 P/Share
|
|
Jun 14
2017
|
David A Ricks President, Chair, and CEO |
SELL
Bona fide gift
|
Direct |
25
-0.02%
|
-
|
|
Jun 12
2017
|
Melissa S Barnes Chief Eth/Cmpl Ofcr & SVP, ERM |
SELL
Open market or private sale
|
Direct |
1,900
-11.92%
|
$152,000
$80.78 P/Share
|
|
Jun 09
2017
|
Michael J Harrington Senior VP and General Counsel |
SELL
Open market or private sale
|
Direct |
22,833
-26.9%
|
$1,803,807
$79.97 P/Share
|
|
May 25
2017
|
John C Lechleiter |
BUY
Bona fide gift
|
Indirect |
387,058
+47.02%
|
-
|
|
May 25
2017
|
John C Lechleiter |
SELL
Bona fide gift
|
Direct |
387,058
-47.02%
|
-
|
|
May 22
2017
|
Jeffrey N Simmons SVP&Pres. Elanco Animal Health |
SELL
Bona fide gift
|
Direct |
6,390
-5.13%
|
-
|
|
May 15
2017
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
120
+4.54%
|
$9,600
$80.3 P/Share
|
|
May 15
2017
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
136
+0.38%
|
$10,880
$80.3 P/Share
|
|
May 05
2017
|
David A Ricks President, Chair, and CEO |
SELL
Bona fide gift
|
Direct |
357
-0.33%
|
-
|